NASDAQ:ONTX - Onconova Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.3750 +0.02 (+5.63 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$0.3750
Today's Range$0.36 - $0.3798
52-Week Range$0.33 - $2.83
Volume844,861 shs
Average Volume1.22 million shs
Market Capitalization$27.94 million
P/E Ratio-0.14
Dividend YieldN/A
Beta0.41

About Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics logoOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONTX
CUSIPN/A
Phone267-759-3680

Debt

Debt-to-Equity RatioN/A
Current Ratio0.81
Quick Ratio0.81

Price-To-Earnings

Trailing P/E Ratio-0.14
Forward P/E Ratio-0.38
P/E GrowthN/A

Sales & Book Value

Annual Sales$790,000.00
Price / Sales36.84
Cash FlowN/A
Price / CashN/A
Book Value($0.09) per share
Price / Book-4.17

Profitability

EPS (Most Recent Fiscal Year)($2.68)
Net Income$-24,090,000.00
Net Margins-1,826.64%
Return on EquityN/A
Return on Assets-216.65%

Miscellaneous

Employees25
Outstanding Shares77,610,000

Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Onconova Therapeutics shares reverse split before market open on Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics Inc. (NASDAQ:ONTX) released its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.05. The biopharmaceutical company earned $0.56 million during the quarter, compared to analysts' expectations of $0.48 million. View Onconova Therapeutics' Earnings History.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Onconova Therapeutics.

What price target have analysts set for ONTX?

3 brokerages have issued twelve-month price objectives for Onconova Therapeutics' shares. Their forecasts range from $3.00 to $6.00. On average, they anticipate Onconova Therapeutics' stock price to reach $4.50 in the next year. View Analyst Ratings for Onconova Therapeutics.

What are Wall Street analysts saying about Onconova Therapeutics stock?

Here are some recent quotes from research analysts about Onconova Therapeutics stock:
  • 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (5/19/2018)
  • 2. Maxim Group analysts commented, "Summary We discuss in more detail below the meaning of the Interim analysis and the path to approval, including timelines and costs. Can Onconova get there? There are hurdles (aren’t there for most microcap biotech companies?), but we believe they can eventually, based on the fundamental prospects of Rigosertib." (3/26/2018)
  • 3. HC Wainwright analysts commented, "Buy-rated Cytori Therapeutics, Inc. (CYTX, $0.70 PT) reported 4Q17 results AMC Thursday, 3/8/2018, and held a corresponding conference call at 5:30pm ET. CYTX posted a top line/ EPS/adj. EBITDA of $1.5M/($0.20)/($2.9)M versus our estimate of $2.0M/($0.10)/($3.3)M and consensus $2.6M/($0.10)/($1.7)M. The revenue miss was primarily due to lower Celution Systems sales in Japan as 4Q government contract revenue through BARDA for the R&D of medical countermeasures for thermal burns of $0.9M was just shy of our $1.0M estimate. BARDA revenues should continue to increase as CYTX gets ready to commence its pilot trial (for additional info, see Quick Note dated 6/1/17). Meanwhile, CYTX’s EPS would have been in line with our projection but the company recognized $4.0M in one-time non-cash expenses related to a beneficial conversion feature for convertible preferred stock. CYTX’s adj." (3/9/2018)

Are investors shorting Onconova Therapeutics?

Onconova Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 852,160 shares, a decrease of 43.2% from the April 30th total of 1,499,501 shares. Based on an average trading volume of 1,305,010 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.2% of the shares of the company are short sold.

Who are some of Onconova Therapeutics' key competitors?

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the folowing people:
  • Dr. Ramesh Kumar, Co-Founder, CEO, Pres & Director (Age 62)
  • Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 55)
  • Dr. Steven M. Fruchtman, Chief Medical Officer and Sr. VP of R&D (Age 67)
  • Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 74)
  • Mr. Mark Patrick Guerin, CFO & Principal Accounting Officer (Age 49)

Has Onconova Therapeutics been receiving favorable news coverage?

News headlines about ONTX stock have been trending positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Onconova Therapeutics earned a coverage optimism score of 0.30 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 44.00 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (1.97%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.

Which major investors are selling Onconova Therapeutics stock?

ONTX stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Onconova Therapeutics.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $0.3750.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $27.94 million and generates $790,000.00 in revenue each year. The biopharmaceutical company earns $-24,090,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]


MarketBeat Community Rating for Onconova Therapeutics (ONTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  153 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  287
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Onconova Therapeutics (NASDAQ:ONTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Onconova Therapeutics in the last 12 months. Their average twelve-month price target is $4.50, suggesting that the stock has a possible upside of 1,100.00%. The high price target for ONTX is $6.00 and the low price target for ONTX is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.752.753.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.50$8.00$7.3333$7.3333
Price Target Upside: 1,100.00% upside751.06% upside326.36% upside283.94% upside

Onconova Therapeutics (NASDAQ:ONTX) Consensus Price Target History

Price Target History for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ:ONTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018HC WainwrightSet Price TargetBuy$3.00HighView Rating Details
5/2/2018Maxim GroupUpgradeHold ➝ BuyMediumView Rating Details
7/25/2017Dawson JamesReiterated RatingBuyHighView Rating Details
4/27/2017LaidlawInitiated CoverageBuy ➝ Buy$10.00LowView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Onconova Therapeutics (NASDAQ:ONTX) Earnings History and Estimates Chart

Earnings by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ:ONTX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS

Onconova Therapeutics (NASDAQ ONTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018($0.29)N/AView Earnings Details
5/15/2018Q1 2018($0.39)($0.34)$0.48 million$0.56 millionViewListenView Earnings Details
3/8/2018Q4 2017($0.69)($0.59)$0.31 million$0.14 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.73)($0.71)$0.29 million$0.11 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.72)($0.29)$0.25 million$0.32 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.96)($1.23)$0.21 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.54)$0.17 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.82)($0.29)$1.60 million$1.70 millionViewN/AView Earnings Details
8/15/2016Q2($1.96)$2.25 millionViewN/AView Earnings Details
5/11/2016Q1($0.19)($0.27)$1.34 million$1.47 millionViewN/AView Earnings Details
3/28/2016Q4($0.27)$0.18$9.60 millionViewN/AView Earnings Details
11/11/2015Q3($0.32)($0.26)$0.11 million$1.62 millionViewN/AView Earnings Details
8/13/2015Q2($0.56)($0.41)$0.11 million$0.12 millionViewN/AView Earnings Details
5/14/2015Q1($0.63)($0.57)$0.11 million$0.11 millionViewN/AView Earnings Details
3/26/2015($0.71)($0.62)$0.11 millionViewN/AView Earnings Details
11/13/2014($0.78)($0.69)$0.11 millionViewN/AView Earnings Details
8/13/2014($0.89)($0.77)$0.56 million$0.13 millionViewN/AView Earnings Details
5/12/2014($0.78)($0.87)$1.32 million$0.45 millionViewN/AView Earnings Details
3/10/2014Q4 13($1.07)($0.68)$1.07 million$1.93 millionViewN/AView Earnings Details
11/12/2013Q3($0.66)($1.34)$1.07 million$1.12 millionViewListenView Earnings Details
9/6/2013Q213($5.21)$0.22 million$0.5910 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Onconova Therapeutics (NASDAQ:ONTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Onconova Therapeutics (NASDAQ ONTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.70%
Institutional Ownership Percentage: 35.02%
Insider Trading History for Onconova Therapeutics (NASDAQ:ONTX)
Institutional Ownership by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

Onconova Therapeutics (NASDAQ ONTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/27/2018683 Capital Management, LlcMajor ShareholderBuy11,838,235$0.43$5,090,441.05View SEC Filing  
2/8/2018683 Capital Management, LlcMajor ShareholderBuy200,000$1.04$208,000.00View SEC Filing  
4/26/2017E Premkumar ReddyDirectorBuy119,048$2.10$250,000.80385,832View SEC Filing  
4/26/2017Mark Patrick GuerinCFOBuy1,429$2.10$3,000.905,155View SEC Filing  
4/26/2017Ramesh KumarInsiderBuy23,810$2.10$50,001.00View SEC Filing  
2/21/2014& Jane Hoffman 2013 De Michaelmajor shareholderBuy143,480$8.47$1,215,275.604,518,275View SEC Filing  
2/10/2014Ramesh KumarCEOSell33,543$15.07$505,493.01View SEC Filing  
2/3/2014Ramesh KumarCEOSell60,000$15.05$903,000.00View SEC Filing  
1/27/2014Michael HoffmanDirectorBuy57,295$11.92$682,956.40View SEC Filing  
11/22/2013Michael HoffmanDirectorBuy5,000$14.39$71,950.00View SEC Filing  
11/18/2013E Premkumar ReddyDirectorBuy5,000$12.10$60,500.001,278,718View SEC Filing  
11/15/2013& Jane Hoffman 2013 De Michaelmajor shareholderBuy19,700$11.99$236,203.004,307,500View SEC Filing  
11/15/2013Henry BienenDirectorBuy1,400$12.17$17,038.0014,935View SEC Filing  
11/15/2013Ramesh KumarCEOBuy1,100$12.02$13,222.00View SEC Filing  
7/30/2013& Jane Hoffman 2013 De MichaelMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
7/30/2013Ramesh KumarCEOBuy6,667$15.00$100,005.00View SEC Filing  
7/30/2013Thomas J MckearnInsiderBuy3,333$15.00$49,995.00View SEC Filing  
7/30/2013Viren MehtaDirectorBuy16,667$15.00$250,005.00View SEC Filing  
7/25/2013E Premkumar ReddyDirectorBuy1,000$22.72$22,720.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Onconova Therapeutics (NASDAQ ONTX) News Headlines

Source:
DateHeadline
Who Are The Top Investors In Onconova Therapeutics Inc (NASDAQ:ONTX)?Who Are The Top Investors In Onconova Therapeutics Inc (NASDAQ:ONTX)?
finance.yahoo.com - May 26 at 9:54 AM
Onconova Therapeutics (ONTX) Lifted to "Buy" at Zacks Investment ResearchOnconova Therapeutics (ONTX) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 19 at 10:57 AM
Edited Transcript of ONTX earnings conference call or presentation 15-May-18 1:00pm GMTEdited Transcript of ONTX earnings conference call or presentation 15-May-18 1:00pm GMT
finance.yahoo.com - May 17 at 10:16 AM
Onconova Therapeutics (ONTX) Releases Quarterly  Earnings Results, Beats Expectations By $0.05 EPSOnconova Therapeutics (ONTX) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS
www.americanbankingnews.com - May 16 at 9:56 AM
Onconova Therapeutics (ONTX) CEO Ramesh Kumar on Q1 2018 Results - Earnings Call TranscriptOnconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 3:53 PM
Onconova Therapeutics (ONTX) Given a $3.00 Price Target at HC WainwrightOnconova Therapeutics (ONTX) Given a $3.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 15 at 1:31 PM
Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018
finance.yahoo.com - May 15 at 10:47 AM
Analysts Expect Breakeven For Onconova Therapeutics Inc (NASDAQ:ONTX)Analysts Expect Breakeven For Onconova Therapeutics Inc (NASDAQ:ONTX)
finance.yahoo.com - May 15 at 10:47 AM
Onconova Therapeutics Inc. (ONTX) Sees Large Increase in Short InterestOnconova Therapeutics Inc. (ONTX) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 13 at 1:40 AM
Zacks Investment Research Downgrades Onconova Therapeutics (ONTX) to HoldZacks Investment Research Downgrades Onconova Therapeutics (ONTX) to Hold
www.americanbankingnews.com - May 10 at 11:28 AM
Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2018 Financial ResultsOnconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 10:08 AM
Onconova Therapeutics (ONTX) Scheduled to Post Quarterly Earnings on MondayOnconova Therapeutics (ONTX) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 7 at 3:14 AM
Rounds Report: Nephros Rallied While The Eleven Train Continued To Head Further NorthRounds Report: Nephros Rallied While The Eleven Train Continued To Head Further North
seekingalpha.com - May 3 at 9:59 AM
Onconova Therapeutics to Present at the Disruptive Growth and Healthcare Conference on May 8th, 2018Onconova Therapeutics to Present at the Disruptive Growth and Healthcare Conference on May 8th, 2018
finance.yahoo.com - May 3 at 9:59 AM
Onconova Therapeutics (ONTX) Raised to Buy at ValuEngineOnconova Therapeutics (ONTX) Raised to Buy at ValuEngine
www.americanbankingnews.com - May 2 at 10:58 PM
UPDATE: Maxim Group Upgrades Onconova Therapeutics (ONTX) to BuyUPDATE: Maxim Group Upgrades Onconova Therapeutics (ONTX) to Buy
www.streetinsider.com - May 2 at 3:55 PM
Onconova Therapeutics (ONTX) Raised to "Buy" at Maxim GroupOnconova Therapeutics (ONTX) Raised to "Buy" at Maxim Group
www.americanbankingnews.com - May 2 at 2:36 PM
Onconova Therapeutics Inc (NASDAQ:ONTX): Does The Earnings Decline Make It An Underperformer?Onconova Therapeutics Inc (NASDAQ:ONTX): Does The Earnings Decline Make It An Underperformer?
finance.yahoo.com - May 2 at 10:02 AM
Onconova Therapeutics Announces Closing of $28.75 Million Upsized Underwritten Public OfferingOnconova Therapeutics Announces Closing of $28.75 Million Upsized Underwritten Public Offering
finance.yahoo.com - May 2 at 10:02 AM
Onconova Therapeutics Inc. (ONTX) Major Shareholder 683 Capital Management, Llc Purchases 11,838,235 SharesOnconova Therapeutics Inc. (ONTX) Major Shareholder 683 Capital Management, Llc Purchases 11,838,235 Shares
www.americanbankingnews.com - May 1 at 7:18 PM
Onconova prices stock offering; shares down 7% premarketOnconova prices stock offering; shares down 7% premarket
seekingalpha.com - April 27 at 10:47 AM
Onconova Therapeutics (ONTX) Upgraded to "Buy" at Zacks Investment ResearchOnconova Therapeutics (ONTX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 25 at 9:22 AM
BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research ...BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research ...
www.reuters.com - April 20 at 10:16 AM
Onconova Therapeutics (ONTX) Reports Data on Dual Inhibitor of CDK4/6 Plus ARK5 at 2018 AACR MeetingsOnconova Therapeutics (ONTX) Reports Data on Dual Inhibitor of CDK4/6 Plus ARK5 at 2018 AACR Meetings
www.streetinsider.com - April 20 at 10:16 AM
Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual MeetingOnconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting
finance.yahoo.com - April 19 at 10:18 AM
Onconova Therapeutics (ONTX) Stock Rating Lowered by Zacks Investment ResearchOnconova Therapeutics (ONTX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 19 at 9:05 AM
Onconova readies equity offering; shares down 4% premarketOnconova readies equity offering; shares down 4% premarket
seekingalpha.com - April 18 at 10:18 AM
Onconova Therapeutics (ONTX) Upgraded by Zacks Investment Research to "Buy"Onconova Therapeutics (ONTX) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 18 at 10:04 AM
Onconova Therapeutics Inc. (ONTX) Receives Average Rating of "Buy" from AnalystsOnconova Therapeutics Inc. (ONTX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 16 at 1:42 AM
Onconova Therapeutics Inc. (ONTX) Sees Large Growth in Short InterestOnconova Therapeutics Inc. (ONTX) Sees Large Growth in Short Interest
www.americanbankingnews.com - April 14 at 1:41 AM
Onconova Therapeutics (ONTX) Stock Rating Reaffirmed by Maxim GroupOnconova Therapeutics (ONTX) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - April 1 at 11:24 PM
Edited Transcript of ONTX earnings conference call or presentation 8-Mar-18 2:00pm GMTEdited Transcript of ONTX earnings conference call or presentation 8-Mar-18 2:00pm GMT
finance.yahoo.com - April 1 at 10:16 AM
Onconova Therapeutics (ONTX) PT Set at $8.00 by HC WainwrightOnconova Therapeutics (ONTX) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - March 26 at 1:24 PM
Onconova Therapeutics (ONTX) Given "Hold" Rating at Maxim GroupOnconova Therapeutics (ONTX) Given "Hold" Rating at Maxim Group
www.americanbankingnews.com - March 26 at 1:24 PM
Onconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease SymposiumOnconova Presents Promising Data from Phase 2 Expansion Study of Oral Rigosertib and Azacitidine Combination in Patients with Myelodysplastic Syndromes at 6th International Bone Marrow Failure Disease Symposium
finance.yahoo.com - March 26 at 10:57 AM
Onconova Therapeutics Inc (ONTX) Given Consensus Rating of "Buy" by AnalystsOnconova Therapeutics Inc (ONTX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 22 at 1:36 AM
Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American ... - GlobeNewswire (press release)Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American ... - GlobeNewswire (press release)
globenewswire.com - March 16 at 3:56 PM
Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018Onconova Therapeutics to Present Data on a First-in-class Dual Inhibitor of CDK4/6 + ARK5 at the American Association for Cancer Research Annual Meeting 2018
finance.yahoo.com - March 15 at 11:01 AM
Onconova Therapeutics (ONTX) Upgraded to "Hold" at ValuEngineOnconova Therapeutics (ONTX) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - March 14 at 11:22 PM
Onconova Therapeutics (ONTX) versus Trius Therapeutics (TSRX) Financial AnalysisOnconova Therapeutics (ONTX) versus Trius Therapeutics (TSRX) Financial Analysis
www.americanbankingnews.com - March 14 at 7:52 PM
Onconova Therapeutics (ONTX) Releases  Earnings Results, Beats Estimates By $0.10 EPSOnconova Therapeutics (ONTX) Releases Earnings Results, Beats Estimates By $0.10 EPS
www.americanbankingnews.com - March 9 at 4:27 PM
Onconova Therapeutics (ONTX) CEO Ramesh Kumar on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaOnconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 4:03 PM
Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2017 Financial Results - GlobeNewswire (press release)Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 9 at 4:03 PM
Onconova Therapeutics (ONTX) Earns Hold Rating from Maxim GroupOnconova Therapeutics (ONTX) Earns Hold Rating from Maxim Group
www.americanbankingnews.com - March 9 at 1:51 PM
Onconova Therapeutics to Present at the 30th Annual Roth Conference in March - GlobeNewswire (press release)Onconova Therapeutics to Present at the 30th Annual Roth Conference in March - GlobeNewswire (press release)
globenewswire.com - March 6 at 3:50 PM
Onconova (ONTX) Announces License Agreement with Pint Pharma to Commercialize Rigosertib in Latin AmericaOnconova (ONTX) Announces License Agreement with Pint Pharma to Commercialize Rigosertib in Latin America
www.streetinsider.com - March 6 at 10:36 AM
Onconova Therapeutics to Present at the 30th Annual Roth Conference in MarchOnconova Therapeutics to Present at the 30th Annual Roth Conference in March
finance.yahoo.com - March 6 at 10:36 AM
Onconova Announces Presentation of Mechanism of Action Studies ... - GlobeNewswire (press release)Onconova Announces Presentation of Mechanism of Action Studies ... - GlobeNewswire (press release)
globenewswire.com - March 5 at 4:02 PM
Onconova (ONTX) Announces License Agreement with Pint Pharma ... - StreetInsider.comOnconova (ONTX) Announces License Agreement with Pint Pharma ... - StreetInsider.com
www.streetinsider.com - March 5 at 4:02 PM
Onconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin AmericaOnconova Therapeutics Announces License Agreement with Pint Pharma to Commercialize Rigosertib for Treatment of Myelodysplastic Syndromes in Latin America
finance.yahoo.com - March 5 at 11:13 AM

SEC Filings

Onconova Therapeutics (NASDAQ:ONTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Onconova Therapeutics (NASDAQ:ONTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Onconova Therapeutics (NASDAQ ONTX) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.